VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients
25 juil. 2023 09h08 HE
|
Oncocyte Corporation
- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal IRVINE,...
Oncocyte Announces 1-For-20 Reverse Stock Split
24 juil. 2023 13h35 HE
|
Oncocyte Corporation
IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20...
Oncocyte Begins Manufacturing Transplant Blood Test
27 juin 2023 08h30 HE
|
Oncocyte Corporation
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics...
Oncocyte Reports First Quarter 2023 Financial Results
11 mai 2023 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31,...
Oncocyte To Announce First Quarter 2023 Financial Results
27 avr. 2023 16h59 HE
|
Oncocyte Corporation
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial...
Oncocyte Presents New Data at AACR
18 avr. 2023 08h45 HE
|
Oncocyte Corporation
IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at...
Oncocyte Announces Reduction in Force
12 avr. 2023 16h15 HE
|
Oncocyte Corporation
IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its...
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
07 avr. 2023 08h24 HE
|
Oncocyte Corporation
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study...
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
03 avr. 2023 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, announced today the entry into an agreement...
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
31 mars 2023 17h00 HE
|
Oncocyte Corporation
IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and...